Transcode Therapeutics, Inc. (RNAZ) income statement
RNAZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$1.34−0.06 (-4.61%)
Close on Nov 18, 2026Market cap $1.36MP/E –Yield –
Transcode Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -833.5%
Financial strength
- Current ratio
- 1.97
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 155.3%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?